Brivaracetam
Contents
Description
Brivaracetam is a high-affinity synaptic vesicle protein 2A (SV2A) ligand indicated as adjunctive therapy for partial-onset seizures in patients 1 month of age and older with epilepsy. It received orphan drug designation for progressive myoclonic epilepsy and has been studied in various epilepsy syndromes. The drug may be relevant for neuronal ceroid lipofuscinosis variants that present with progressive epilepsy.
Indications & Therapeutic Use
partial-onset seizures, adjunctive therapy in epilepsy
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Brivaracetam — GNH India
109 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | brivaracetam |
| Brands | 1 brand available |
| Active Ingredient | brivaracetam |
| Drug Class | partial-onset seizures |
| Manufacturer | UCB Pharma |
| Dosage Forms | oral tablet, 10mg, 25mg, 50mg, 75mg, 100mg; oral solution, 10mg/mL; IV injection, 50mg/5mL |
| Medical Code | N03AX23 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01261325 |
| Countries | 8 countries |